GlobalData : Sanofi's Dupixent likely to see label expansion to young eosinophilic esophagitis patients soon after approval in adults, says GlobalData - Marketscreener.com
4/6/2022 12:00:00 AM3 years 10 months ago
by MarketScreener
by MarketScreener
06 Apr 2022 Sanofi's Dupixent likely to see label expansion to young eosinophilic esophagitis patients soon after approval in adults, says GlobalData Posted in... | April 8, 2022
Following the news that Sanofi and Regeneron announced that the Food and Drug Administration (FDA) accepted a Priority Review of the supplemental Biologics License Application (sBLA) for Dupixent (du… [+1591 chars]
full article...